Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
The drug product(s) listed below are eligible for coverage via the step therapy/special authorization process.
FIRST-LINE DRUG PRODUCT(S): DOXAZOSIN OR TERAZOSIN
"For the treatment of the symptoms of benign prostatic hyperplasia (BPH) in patients who are unresponsive to a six-week trial with a non-selective alpha-blocker (e.g., terazosin ) or in whom non-selective alpha-blockers are not tolerated or are contraindicated."
"Special authorization may be granted for 24 months"
Note: If a claim for the Step therapy drug product is rejected, pharmacists can use their professional judgment to determine the appropriateness of using the intervention code(s) noted below to re-submit a claim. The pharmacist is responsible to document on the patient's record the rationale for using the second-line therapy drug.
UP - First-line therapy ineffective UQ - First-line therapy not tolerated
Review Status / Past Decisions
Indication
Reviewing Body
Submission Completion Date
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
Review Status
N/A
Expert Committee
2003/08/14
2009/07/01
Change to Step Therapy/Special Authorization
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2003/08/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2009/07/01
CDR Recommendation
Review Status
Change to Step Therapy/Special Authorization
SANOFI - AVENTIS (SAV)
Telephone:(514) 956-6200
Toll-Free:(800) 363-6364
To return to the printable Drug Benefit List and related publications,
click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.